CHRONIC ATYPICAL NEUROLEPTIC TREATMENT IN NORMALLY DEVELOPING MACACA NEMESTRINA

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Atypical neuroleptic drugs are being used frequently in children and adolescents with severe psychopathology. The effects of these agents on normal growth and development are unknown. This 5-year project treats normally developing non-human primates (macaque nemestrina) with risperidone, quetiapine, or placebo from 13-20 months of age, followed by a 4 month post-drug period. 12 males will receive a low dose of risperidone or quetiapine for 4 months, then switched to a high dose for 4 months. 24 males will be assigned to the placebo condition. Animals are being tested before, during, and after drug or placebo treatment for (1) social, emotional, exploratory, learning and memory, motor skill, and perceptual behavior; and (2) physical assessments of health, somatic growth, bone mineralization, and hormonal function. The study design permits both between-group and within-individual comparisons to examine drug group differences as well as dose effects. Since m. nemestrina monkeys demonstrate psychological and somatic development comparable to humans, this project will identify aspects of human development that are likely to be affected by chronic treatment with these agents. 12-20 monkeys will be studied each year, with 20 currently being tested.